Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite® immunochemiluminescent third-generation assay: Potential applications in prostate and breast cancers

Clinical Chemistry

Volumn 42, Issue 5, 1996, Pages 675-684

  Ferguson, Ralph A ^b   Yu, He ^b   Kalyvas, Maria ^b   Zammit, Sonya ^b   Diamandis, Eleftherios P ^a  

^a Mt Sinai Hospital

^b NONE

Author keywords

Clinical chemistry analyzer; Tumor markers

Indexed keywords

CHYMOTRYPSIN INHIBITOR; ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TISSUE EXTRACT;

ARTICLE; AUTOANALYZER; BREAST CANCER; CALIBRATION; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOSOL; FEMALE; FLUOROIMMUNOASSAY; HUMAN; HUMAN TISSUE; PATIENT MONITORING; PROSTATE CANCER; PROSTATECTOMY; TIME;

BREAST NEOPLASMS; CHEMILUMINESCENT MEASUREMENTS; CYTOSOL; DRUG STABILITY; FEMALE; FLUOROIMMUNOASSAY; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0029986012     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.5.675     Document Type: Article

References (38)

1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-63.
2. Hara M, Kimura H. Two prostate-specific antigens, γ-seminoprotein and β-microseminoprotein. J Lab Clin Med 1989;113:541-8.
3. Graves HCB, Sensabaugh GF, Blake RT. Postcoital detection of male-specific semen protein. Application to the investigation of rape. N Engl J Med 1985;312:338-43.
4. Watt KWK, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci U S A 1986;83:3166-70.
5. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76: 1899-903.
6. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Mesurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324: 1156-61.
7. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society Guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993;43:42-6.
8. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994;272:773-9.
9. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994;152: 1905-9.
10. Littrup PJ, Goodman AC, Mettlin CJ, Murphy GP. Cost analysis of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994;152:1873-7.
11. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate [Review]. J Urol 1991;145:907-23.
12. Armbruster DA. Prostate specific antigen: biochemistry, analytical methods, and clinical application [Review]. Clin Chem 1993;39: 181-95.
13. Leo ME, Bilhartz DL, Bergstrahl EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 1991;145: 802-6.
14. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 1989; 142:1011-7.
15. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
16. Oesterling JE, Chan DW, Epstein JI, Kimball AW Jr, Bruzek DJ, Rock RC, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
17. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value o1 serum prostate specific artigen determinations before and after radical prostatectomy. J Urol 1989;141:873-9.
18. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha FS, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients J Urol 1989;141:1076-83.
19. Yu H, Diamandis EP. Ultrasensitive time-resolved immunofluorometric assay of prostate specific antigen in serum and preliminary clinical studies. Clin Chem 1993;39:2108-14.
20. Stamey TA, Graves HCB, Wehner N, Ferrari M, Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 1993;149:787-92.
21. Yu H, Diamandis EP, Prestigiacomo AF, Stamey TA. Ultrasensitive assay of prostate specific antigen used for early detection of prostate cancer relapse and estimation of tumor doubling time after radical prostatectomy. Clin Chem 1995;41:430-4.
22. Yu H, Diamandis EP. Prostate-specific antigen in the milk of lactating women. Clin Chem 1995;41:54-60.
23. Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995;41:204-10.
24. van Krieken JH. Prostate marker immunoreactivity in salivary gland neoplasms. A rare pitfall in immunohistochemistry. Am J Surg Pathol 1993;17:410-4.
25. Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994;78:1536-9.
26. Monne M, Croce CM, Yu H, Diamandis EP. Molecular characterization of prostate-specific antigen mRNA express in breast tumors. Cancer Res 1994;54:6344-7.
27. Levesque M, Yu H, D'Costa M, Diamandis EP. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 1995;9: 123-8.
28. Diamandis EP, Yu H, Sutherland DJA. Detection of prostate-specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 1994;32:291-300.
29. Yu H, Diamandis EP, Sutherland DJA. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994;27:75-9.
30. Christopoulos TK, Diamandis EP. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal Chem 1992;64:342-6.
31. Papanastasiou-Diamandi A, Christopoulos TK, Diamandis EP. Ultrasensitive thyrotropin immunoassay based on enzymatically amplified time-resolved fluorescence with a terbium chelate. Clin Chem 1992;38:545-8.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265-75.
33. NCCLS Document EP10-T Vol. 9 (3). Preliminary evaluation of clinical chemistry methods. Villanova, PA: National Committee for Clinical Laboratory Standards, 1990.
34. Graves HCB, Wehner N, Stamey TA. Ultrasensitive radioimmunoassay of prostate-specific antigen. Clin Chem 1992;38:735-42.
35. Vessela RL, Noteboom J, Lange PH. Evaluation of the Abbott IMx® automated immunoassay of prostate specific antigen. Clin Chem 1992;38:2044-54.
36. Ferguson RA, Mee AV, Wong PY. Comparative evaluation of serum prostate specific antigen (PSA) analysis by the Abbott AxSYM® and IMx® analyzers. J Clin Ligand Assay. In press.
37. Graves HCB. Standardization of immunoassays for prostate-specific antigen: a problem of prostate-specific antigen complexation or a problem of assay design. Cancer 1993;72:3141-4.
38. Vessella RL. Trends in immunoassays of prostate-specific antigen: serum complexes and ultrasensitivity [Editorial]. Clin Chem 1993;2035-9.